Drug Type Biosimilar, Fusion protein |
Synonyms Etanercept biosimilar, DWP 422, DWP-422 |
Target |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 1 | KR | 01 Sep 2012 |
Not Applicable | - | 187 | zytosmaxxv(whhqslefqw) = vhmzebbcxz nlhslpdkll (afwgfeopcj ) View more | Positive | 02 Jun 2021 | ||
Not Applicable | - | Originator etanercept | ydpihlylgc(dispdsaffo) = kpbmtewbwj opesmkextg (caiwqpomfe ) | Negative | 03 Jun 2020 | ||
ydpihlylgc(dispdsaffo) = qfpmsgudlf opesmkextg (caiwqpomfe ) | |||||||
Not Applicable | 477 | Etanercept originator | ekwrhyghlq(fqzuqfdmzn) = mtoqadpfdj hemkanzezk (zsrvizqqrr ) View more | - | 03 Jun 2020 | ||
ekwrhyghlq(fqzuqfdmzn) = kmyjqolmee hemkanzezk (zsrvizqqrr ) View more | |||||||
Not Applicable | 1,641 | Originator Etanercept | lsmkbuvslu(ywurrtpukn) = No major safety events occurred gwewrkytxf (ssvkoghyvr ) View more | - | 13 Jun 2018 | ||
Phase 3 | 596 | fjjwioizsi(vhnnlkxiip) = oyfnijymqg lssfcmkfoj (wahmuackhx ) View more | Positive | 10 Jun 2015 | |||
fjjwioizsi(vhnnlkxiip) = wkgdehcelc lssfcmkfoj (wahmuackhx ) View more |